Despite the development of contemporary surgical management of retroperitoneal liposarcomas, local recurrence remains the major challenge in the treatment of these tumors. Currently, surgery is the main treatment option for liposarcoma. The international cancer community faces a global goal — the development of new combined treatment options for the treatment of retroperitoneal liposarcoma to reduce the postoperative recurrence rate and increase the overall survival. This article presents the world literature data on the treatment of retroperitoneal liposarcomas and demonstrates a case report describing treatment of a patient with this disease in the N. N. Blokhin NMRC of Oncology.
Stereotactic body radiotherapy for early stage non-small-cell lung cancer was, is, and will remain the key subject of discussions between radiation oncologists and surgeons. Despite the positive treatment outcomes reported in some large studies on efficacy of the stereotactic radiotherapy, its use instead of surgery may not always be an unconditional decision. However, stereotactic radiotherapy opens new treatment options in patients who are inoperable or refused surgery. This is possibly due to the high accuracy of modern linear accelerators, which allow to reduce the toxicity of radiotherapy and achieve an almost identical overall survival rate compared to surgery.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.